Anemia News and Research

RSS
Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.
G1 HCV patients having fast antiviral response to TVR with PEG-IFN and RBV can be cured in 24 weeks

G1 HCV patients having fast antiviral response to TVR with PEG-IFN and RBV can be cured in 24 weeks

Socioeconomic factors linked to rates and outcomes of stem cell transplantation for AML patients

Socioeconomic factors linked to rates and outcomes of stem cell transplantation for AML patients

Alexion Pharmaceuticals' Soliris NDA for PNH receives approval in Japan

Alexion Pharmaceuticals' Soliris NDA for PNH receives approval in Japan

Data from Phase 2 clinical trials of Hematide/peginesatide presented at NKF Annual Meeting

Data from Phase 2 clinical trials of Hematide/peginesatide presented at NKF Annual Meeting

Genocea Biosciences, NMRC sign CRADA to develop vaccine against malaria

Genocea Biosciences, NMRC sign CRADA to develop vaccine against malaria

Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting

Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting

Survey reveals Gamunex as preferred IGIV therapy among neurologists

Survey reveals Gamunex as preferred IGIV therapy among neurologists

Clinical and preclinical malaria vaccine data presented at Keystone Symposium

Clinical and preclinical malaria vaccine data presented at Keystone Symposium

BeaconEquity.com releases investment report on Cord Blood America

BeaconEquity.com releases investment report on Cord Blood America

Kidney disease genes discovered

Kidney disease genes discovered

Telaprevir-based regimens increase rates of SVR in patients with genotype 1 HCV infection

Telaprevir-based regimens increase rates of SVR in patients with genotype 1 HCV infection

Folate increases risk of breast cancer in women with certain genetic make-up

Folate increases risk of breast cancer in women with certain genetic make-up

StockPreacher.com releases investment report on Repros Therapeutics

StockPreacher.com releases investment report on Repros Therapeutics

Innovative drug design wins medical research prize

Innovative drug design wins medical research prize

AMAG Pharmaceuticals, Takeda Pharmaceutical announce Feraheme collaboration

AMAG Pharmaceuticals, Takeda Pharmaceutical announce Feraheme collaboration

New medicines to fight diseases of particular concern to African Americans

New medicines to fight diseases of particular concern to African Americans

Dr. Ingmar Bruns selected as seventh recipient of EHA-ASH Research Exchange Award

Dr. Ingmar Bruns selected as seventh recipient of EHA-ASH Research Exchange Award

NKF 2010 Spring Clinical Meeting: Multiple posters on Hematide/peginesatide to be presented

NKF 2010 Spring Clinical Meeting: Multiple posters on Hematide/peginesatide to be presented

YM BioSciences receives approval to expand enrolment in Phase I/II clinical trial of CYT387

YM BioSciences receives approval to expand enrolment in Phase I/II clinical trial of CYT387

Ligand Pharmaceuticals' LGD-4033 SARM Phase I study data featured at 14th endocrinology congress

Ligand Pharmaceuticals' LGD-4033 SARM Phase I study data featured at 14th endocrinology congress

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.